Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up. In its third-quarter results update ...

GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.

GlaxoSmithKline), a pleuromutilin approved in 2008; and tigecycline (Tygacil; Pfizer), a next-generation tetracycline approved in 2005. The reasons behind the decline in antibiotic research and ...

Mold-Tek Technologies Ltd., incorporated in the year 1985, is a Small Cap company (having a market cap of Rs 438.12 Crore) operating in Diversified sector. Mold-Tek Technologies Ltd. key ...